10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2019 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 7, 2020) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Cash flows from operating activities: | |||
| Net income | $ 2,115,800 | 2,444,400 | 1,198,500 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 210,300 | 148,200 | 145,500 |
| Non-cash compensation expense | 464,300 | 427,400 | 507,300 |
| Other non-cash items, net | (29,300) | 12,100 | 63,500 |
| Deferred taxes | (130,600) | (140,000) | 318,800 |
| Changes in assets and liabilities: | |||
| Increase in Sanofi, Bayer, and trade accounts receivable | (473,100) | (268,900) | (362,700) |
| Increase in inventories | (335,500) | (387,900) | (314,200) |
| Increase in prepaid expenses and other assets | (130,400) | (55,700) | (113,300) |
| Increase (decrease) in deferred revenue | 294,000 | (194,500) | (113,100) |
| Increase (decrease) in accounts payable, accrued expenses, and other liabilities | 444,500 | 210,000 | (23,200) |
| Total adjustments | 314,200 | (249,300) | 108,600 |
| Net cash provided by operating activities | 2,430,000 | 2,195,100 | 1,307,100 |
| Cash flows from investing activities: | |||
| Purchases of marketable and other securities | (3,202,400) | (1,845,500) | (1,277,200) |
| Sales or maturities of marketable securities | 1,604,200 | 775,600 | 544,600 |
| Capital expenditures | (429,600) | (383,100) | (272,600) |
| Other | 0 | (10,000) | 0 |
| Net cash used in investing activities | (2,027,800) | (1,463,000) | (1,005,200) |
| Cash flows from financing activities: | |||
| Proceeds in connection with finance lease liabilities | 0 | 57,000 | |
| Payments in connection with finance lease liabilities | 0 | (19,900) | |
| Proceeds from issuance of Common Stock | 211,800 | 114,500 | 240,200 |
| Payments in connection with Common Stock tendered for employee tax obligations | (188,000) | (187,200) | (301,700) |
| Repurchases of Common Stock | (275,900) | (4,400) | 0 |
| Net cash used in financing activities | (252,100) | (77,100) | (24,400) |
| Net increase in cash, cash equivalents, and restricted cash | 150,100 | 655,000 | 277,500 |
| Cash, cash equivalents, and restricted cash at beginning of period | 1,480,200 | 825,200 | |
| Cash, cash equivalents, and restricted cash at end of period | 1,630,300 | 1,480,200 | 825,200 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest (net of amounts capitalized) | 25,000 | 22,300 | 18,700 |
| Cash paid for income taxes | 342,300 | 205,600 | 754,800 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |